1. Home
  2. IMAB vs GNLX Comparison

IMAB vs GNLX Comparison

Compare IMAB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • GNLX
  • Stock Information
  • Founded
  • IMAB 2014
  • GNLX 2001
  • Country
  • IMAB United States
  • GNLX United States
  • Employees
  • IMAB N/A
  • GNLX N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMAB Health Care
  • GNLX Health Care
  • Exchange
  • IMAB Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • IMAB 87.2M
  • GNLX 85.0M
  • IPO Year
  • IMAB 2020
  • GNLX 2023
  • Fundamental
  • Price
  • IMAB $0.96
  • GNLX $4.43
  • Analyst Decision
  • IMAB Strong Buy
  • GNLX Strong Buy
  • Analyst Count
  • IMAB 3
  • GNLX 4
  • Target Price
  • IMAB $8.00
  • GNLX $18.25
  • AVG Volume (30 Days)
  • IMAB 354.5K
  • GNLX 290.3K
  • Earning Date
  • IMAB 03-13-2025
  • GNLX 03-31-2025
  • Dividend Yield
  • IMAB N/A
  • GNLX N/A
  • EPS Growth
  • IMAB N/A
  • GNLX N/A
  • EPS
  • IMAB N/A
  • GNLX N/A
  • Revenue
  • IMAB $3,313,984.00
  • GNLX $8,000.00
  • Revenue This Year
  • IMAB N/A
  • GNLX N/A
  • Revenue Next Year
  • IMAB N/A
  • GNLX N/A
  • P/E Ratio
  • IMAB N/A
  • GNLX N/A
  • Revenue Growth
  • IMAB N/A
  • GNLX N/A
  • 52 Week Low
  • IMAB $0.84
  • GNLX $1.60
  • 52 Week High
  • IMAB $2.00
  • GNLX $9.82
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 43.19
  • GNLX 72.82
  • Support Level
  • IMAB $1.03
  • GNLX $3.20
  • Resistance Level
  • IMAB $1.10
  • GNLX $4.23
  • Average True Range (ATR)
  • IMAB 0.06
  • GNLX 0.53
  • MACD
  • IMAB -0.01
  • GNLX 0.09
  • Stochastic Oscillator
  • IMAB 7.58
  • GNLX 86.86

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: